Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial

Asymptomatic left ventricular (LV) dysfunction is highly prevalent in type 2 diabetes patients. Unlike the other hypoglycemic drugs, SGLT2 inhibitors have shown potential benefits for reducing cardiovascular d...

Source: Cardiovascular Diabetology - October 12, 2017 Category: Cardiology Authors: Andrea Natali, Lorenzo Nesti, Iacopo Fabiani, Enrico Calogero and Vitantonio Di Bello Tags: Study Protocol Source Type: research